• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Vagus Nerve Stimulation: A Brief Update

Vagus Nerve Stimulation: A Brief Update

January 1, 2008
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Daniel Carlat, MD

VNS (vagus nerve stimulation) was initially developed and approved for treatment-refractory epilepsy. Cyberonics conducted one sham-controlled study for treatment-resistant depression, and while this double-blind study showed no statistical benefit over placebo, an open-label extension showed enough benefit to impress someone at the FDA. In a controversial decision in which the unanimous rejection of an advisory panel was overturned, the FDA approved VNS for treatment-resistant depression on July 15, 2005.

Since we last covered this issue (TCPR, Jan 2006), neither VNS nor Cyberonics have fared well. A year and a half after the FDA approval, the Cyberonics CEO Robert Cummins resigned amid allegations that he was inappropriately awarded stock options hours after the FDA decision, shortly before Wall Street opened and the value of his stocks soared. A few months after his resignation, there was more bad news: in May 2007, Medicare announced that they would not reimburse for VNS when used for depression, because their review of the data had concluded that it was not effective. The company’s sales have been down 20% since last year, and they are pulling back on their marketing efforts to concentrate on their core epilepsy business.

Medicare has posted its “decision memo” at http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=195. While very long, it makes for an interesting browse, since it reviews all the extant evidence relating to VNS for depression, and includes point-by-point rebuttals of a variety of pro-VNS arguments. Whether you agree with the decision or not, there’s no question that Medicare spent a great deal of time and brainpower poring over this issue.
General Psychiatry
KEYWORDS brain_devices depressive_disorder
    www.thecarlatreport.com
    Issue Date: January 1, 2008
    SUBSCRIBE NOW
    Table Of Contents
    Discontinuing mood stabilizers often leads to relapse during pregnancy
    Adjunctive psychotherapy helpful in bipolar depression
    Vagus Nerve Stimulation: A Brief Update
    Some trouble with Chantix
    Update on ECT
    Transcranial Magnetic Stimulation: The Saga Continues
    Using EEG to Predict Medication Response
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.